諾普信(002215.SZ):實控人及其一致行動人擬減持合計不超4568.78萬股
格隆匯7月1日丨諾普信(002215.SZ)公佈,公司實際控制人及其一致行動人盧柏強、盧翠冬、西藏林芝潤寶盈信實業投資有限公司(“潤寶盈信”)、深圳市融信南方投資有限公司(現更名“深圳市諾普信投資控股有限公司”以下簡稱“諾普信控股”)合計持有公司股份368,743,497股(佔公司總股本的40.35%),擬計劃自本減持計劃公吿之日起15個交易日後的六個月內以集中競價、自本減持計劃公吿之日起3個交易日後6個月內通過大宗交易方式減持公司股份合計不超過4568.78萬股,減持總數不超過公司總股本的5%。其中集中競價交易不超過公司總股本的1%,大宗交易不超過公司總股本的4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.